ABI’s Mass Spec Tools to Play Role in BG, FDA Hepatotoxicity Biomarker Project
 
The US Food and Drug Administration has approved the first phase of a BG Medicine and National Center for Toxicological Research project to develop biomarkers for liver toxicity, BG Medicine said this week.
 
The company also said it will use mass spectrometry technology made by Applied Biosystems, and has named seven pharmaceutical companies that will participate in the project.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.